Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
about
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentThe phosphoinositide 3-kinase isoform PI3Kβ regulates osteoclast-mediated bone resorption in humans and mice.Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers.PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.Discovery and functional characterization of a neomorphic PTEN mutation.L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3KβNovel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.Therapeutic applications of PI3K inhibitors in cardiovascular diseases.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.PI3King the right partner: unique interactions and signaling by p110β.The progress in the research of antiplatelet agents (1995-2017).Antiphospholipid syndrome: an update for clinicians and scientists.Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.[Phosphoinositides: the lipids coordinating cell dynamics].Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells.Antithrombotic phosphoinositide 3-kinase β inhibitors in humans: a 'shear' delight!Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis
P2860
Q33776641-F94A843F-38DF-45D9-9140-97C34A566098Q35040987-231B14F4-08DF-4D06-953F-4FB1B4C52BEEQ35453467-B8C42B67-1DE4-4C94-8300-2541BC71E1D1Q35657827-DFB75A22-E780-4100-91C1-A2B99F49E393Q36274292-BF07EB49-F3BE-458D-BE0D-A3C2AD033CFEQ36300265-9E24C8C7-DB79-44C2-BD82-B84826A5BC12Q36944808-CD59D0C2-1649-40D4-8282-F45DE6B24366Q38081658-838FCDD6-B824-415E-ABDC-47DE45D20A03Q38089742-1C8D608B-E59B-430F-B217-F8AD0865DC99Q38265574-82DF49EB-240E-4BFC-95F5-9207E7C02DB5Q38542387-69184C62-C689-4945-9C5A-7128E2E164BBQ38669003-D5E0E3F2-1C62-47C7-ADCF-55F9925ED1BCQ38679842-9E3D5649-6D83-44A2-9076-29C80A9D1283Q38745816-16DE2B13-9E0A-4479-8E69-7A4F55D082E4Q38759483-18077F60-5169-4B46-B89B-1E459FE326A8Q38961647-6D45D2FF-6C2B-4910-B6FC-5B2A7ED3A6A5Q40813898-E8A17445-BC73-4A33-8BB2-F9611DE07ACDQ40906812-36533361-97DD-4F14-AABF-91A2991A3A52Q42074608-F2963118-C5AE-4483-B5A3-7A69E1FF69C6Q54486471-C7E8009E-8651-4F66-B48B-077FCABF843DQ57159198-48F45C2E-F75F-421B-B5AF-45CAC451C2B5
P2860
Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@en
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@nl
type
label
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@en
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@nl
prefLabel
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@en
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@nl
P2093
P2860
P1476
Human target validation of pho ...... D6482 a novel PI3Kβ inhibitor.
@en
P2093
B M Emanuelsson
D Gustafsson
J A Björkman
J C Ulvinge
M Andersson
O Fjellström
S Nylander
T Inghardt
P2860
P304
P356
10.1111/J.1538-7836.2012.04898.X
P577
2012-10-01T00:00:00Z